N1 Implant
Implantable brain-computer interface device.
SHARK MONEYYACHT CLUBSearch Shark Money
Search public and private companies, people, funds, markets, tools, and research.
Private markets
Health & Frontier Tech · Brain-Computer Interfaces
Neuralink
Develops implantable brain-computer interfaces and robotic surgical systems.
- Research status
- Research coverage
- Headquarters
- Fremont, CA
- Coverage
- 4 product lines mapped
- Last reviewed
- September 2026
Product map
What the company builds
Products and operating platforms help connect company-level news to the revenue pools, customers, competitors, and supply chains it may affect.
R1 Robot
Robotic system for implant placement.
Telepathy
Brain-computer interface program for device control.
Blindsight
Investigational visual-prosthesis program.
01 / THE BUSINESS
How Neuralink creates value.
Develops implantable brain-computer interfaces and robotic surgical systems. The research focus is whether customer adoption can support attractive economics after development, delivery and ongoing service costs.
SectorHealth & Frontier Tech
Founder coverage2 profiles
Research checkedSep 18, 2026
02 / PEOPLE BEHIND THE COMPANY
Meet the builders.
Co-founder
Elon Musk
Elon Musk is a co-founder of Neuralink. The company’s founding and leadership material provides context for its work in brain-computer interfaces.
Explore founderCo-founder
DJ Seo
DJ Seo is a co-founder of Neuralink. The company’s founding and leadership material provides context for its work in brain-computer interfaces.
Explore founderSelected founders; historical founding roles are distinct from current management positions.
03 / CAPITAL & OWNERSHIP
Follow the financing.
Selected disclosed events, newest first. Announcement values describe that transaction and date; they are not current share prices. Debt, equity and secondary transactions are identified separately.
A financing figure is not established here.
Use the original company sources below to check new announcements. We have not substituted an estimate for a disclosed round.
04 / IN THEIR OWN WORDS
Watch. Listen. Form your view.
Lex Fridman Podcast · 2024-08-02
Elon Musk & the Neuralink team
A discussion with the founder and team about brain-computer interfaces and the company’s work.
Watch on YouTube ↗Neuralink
Neuralink — company videos
Product demonstrations, company presentations and original updates. Browse the channel for the latest available material.
Visit original material ↗Interviews reflect the speaker’s perspective at publication. Company statements are not independent verification.
05 / EDITORIAL ANALYSIS
The opportunity. The open questions.
Our interpretation of the business model and cited sources, not a valuation or a recommendation.
The case to investigate
- Human clinical progress and the potential platform value of high-bandwidth neural interfaces.
- A stronger product position becomes economically meaningful when customers renew, expand and pay enough to cover delivery costs.
Pressure-test the thesis
- Patient safety.
- Regulatory uncertainty.
- Long product timelines.
What to watch next
01
Clinical outcomes — what changed in the latest original disclosure?
02
Regulatory milestones — what changed in the latest original disclosure?
03
Device reliability — what changed in the latest original disclosure?
YOUR RESEARCH WORKSPACE
Keep the questions that matter.
Use this checklist to record what you have investigated. Your notes stay in this browser.
06 / RESEARCH TRAIL
Go straight to the source.
Research checked Sep 18, 2026. Selected public disclosures, not a complete capitalization table or securities-filing search. Missing information is left unconfirmed. No investment availability or IPO date is implied.
Human clinical progress and the potential platform value of high-bandwidth neural interfaces.
Private-company information is incomplete, episodic, and difficult to verify. Treat every data point as a starting point for diligence—not a substitute for company-approved materials, legal review, or investment analysis.
Add to my private currentSignals to monitor
Clinical outcomesRegulatory milestonesDevice reliabilityRisks to underwrite
Patient safetyRegulatory uncertaintyLong product timelines Underwriting map
What an investor should actually diligence
Map scientific evidence, regulatory pathway, clinical utility, reimbursement, manufacturing, and cash runway independently. Technical possibility is not the same as a financeable product path.
Buyer map
01
Patients and clinicians
02
Health systems
03
Payers
04
Research and strategic partners
Economics to request
01
Cash runway through next value inflection
02
Trial design and enrollment requirements
03
Manufacturing and quality-system cost
04
Expected pricing and reimbursement pathway
05
Licensing or partnership economics
Moat tests
01
Evidence is reproducible and clinically meaningful
02
Regulatory path is specific and funded
03
Manufacturing can meet required quality
04
Platform creates multiple credible programs
Milestone map
01
Preclinical or clinical readout
02
Regulatory clearance
03
Manufacturing validation
04
Strategic partnership
Comparable lensesMedical devicesBiotechnology platformsResearch toolsNeurotechnology
Underwriting framework
How to diligence Neuralink
A company-specific starting point based on the operating realities of health & frontier tech. Replace assumptions with verified company materials, customer evidence, legal documents, and expert work.
Cash runway through the next clinical milestone
Trial cost and enrollment assumptions
Manufacturing and procedure economics
Reimbursement and addressable patient population
Peer-reviewed or independently reviewed evidence
Regulatory clearance to advance
Durable clinical outcomes
Manufacturing consistency and safety
Clinical-stage biotechnology
Medical devices
Research platforms
Approved standard of care
What is the next value-inflecting endpoint?
What evidence would stop the program?
Can results scale beyond a small cohort?
Who pays and how is adoption delivered?
No securities are offered here.
SMYC does not represent that shares are available, transferable, appropriately priced, or suitable for any person. Private securities are illiquid, speculative, subject to transfer restrictions, and may result in total loss.